Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we tackle hospital-acquired dysphagia—spot it early, screen systematically, intervene fast—to cut pneumonia, malnutrition, and mortality.
We start with the big drivers: critical illness, intubation/mechanical ventilation, tracheostomy, prolonged stay, and neuro disease (esp. acute stroke). In the ICU, post-extubation dysphagia (PED) hits ~12–26%—higher after emergency admits, severe illness, and long ventilation or RRT. Mechanisms stack up: airway trauma, impaired sensorium, neuromuscular/ICU-acquired weakness. On the wards, stroke leads the pack (up to 78%), and older adults/dementia carry heavy risk and consequences.
Why it matters: aspiration pneumonia, malnutrition/dehydration, longer LOS, higher costs, and higher mortality. Dysphagia is under-recognized and under-screened—especially after extubation.
How we find it—screen, then scope:• Universal nurse-led screening before PO in stroke and after extubation in ICU. Fail = NPO + SLP.• Bedside tools (e.g., Yale, GUSS, TOR-BSST) flag risk but miss silent aspiration.• Instrumental testing when unclear or high-risk: VFSS (gold standard) or FEES (bedside, repeatable).• Separate oropharyngeal vs esophageal patterns: initiate EGD/barium/manometry when transport symptoms dominate.
Management—protect the lungs, feed the patient, train the swallow:• NPO until safe plan; upright 30–45°, slow assisted feeding, small sips/bites.• SLP-led strategies: posture (e.g., chin tuck), pacing, exercises; reassess after any neuro change.• Diet texture & liquids per IDDSI—individualize thickened liquids (benefit ≠ universal; watch hydration).• Early enteral nutrition (NG/PEG) if unsafe or inadequate PO.• Oral care bundle to lower pneumonia risk.• Medication hygiene: limit sedatives/anticholinergics/opioids that blunt swallow or sensorium.• ICU specifics: routine PED screen post-extubation, cuff management, early mobility, and wean plans; avoid reflex “regular diet” orders after tube removal.• Stroke specifics: screen before first sip, rapid SLP + VFSS/FEES as needed, start rehab early, and adapt as deficits evolve.• Elderly/dementia: simplify mealtime environment, cueing, hydration prompts, goals-of-care; monitor for silent aspiration.• Esophageal causes: treat the cause—PPI/EoE diet, endoscopic dilation/oncologic workup, or motility therapy—while maintaining safe intake.
Red flags for higher-level care: recurrent coughing/wet voice, oxygen dips with PO, recurrent pneumonia, failure of bedside screen, bulbar weakness, or new neuro deficits.
Quality & safety pearls:• Screen everyone at risk, every time (stroke, post-extubation, neuro, frail).• Don’t “test with a tray.” A failed screen mandates NPO + SLP.• Instrumental confirmation guides targeted therapy and prevents over- or under-restriction.• Track hydration & calories—thickened liquids can quietly dehydrate patients.• Build order sets that auto-trigger SLP, dietitian, oral care, and aspiration precautions.
We close with the Dysphagia Bundle that sticks:(1) Screen before PO (stroke/post-extubation/elderly/neuro).(2) Failed screen → NPO + SLP + VFSS/FEES pathway.(3) IDDSI diet + compensatory maneuvers with education at bedside.(4) Oral care, hydration checks, and med de-sedation.(5) Escalate to GI (EGD/esophagram/manometry) when esophageal features present.(6) Reassess after status changes; step-up/step-down diet based on data.(7) Discharge plan: home exercises, texture guidance, and follow-up SLP.
Bottom line: screen early, instrument wisely, individualize diets, and rehabilitate relentlessly. That’s how you make dysphagia safer in the hospital—and keep aspiration off your problem list.

In this episode of Hospital Medicine Unplugged, we blitz Guillain–Barré Syndrome (GBS)—recognize early, monitor relentlessly, start immunotherapy on time, prevent complications.
We open with the do-firsts in the hospital: admit all suspected GBS; check vital capacity (VC) & negative inspiratory force (NIF) at baseline and serially; continuous telemetry & BP for dysautonomia; early swallow screen to prevent aspiration. Move moderate–severe weakness or bulbar signs to a monitored/ICU setting.
Diagnosis is clinical-first, tests support: rapidly progressive, symmetric weakness with areflexia/hyporeflexia; look for albuminocytologic dissociation on CSF and use NCS to subtype (AIDP vs axonal). Rule out mimics (myelitis, MG crisis, CIP/CIM, botulism, cord compression).
Treatment—build the evidence-based core:• Immunotherapy for non-ambulatory or rapidly progressive patients: IVIg (2 g/kg over 5 days) or plasma exchange (PE; 4–5 exchanges over ~2 weeks)—equally effective for speeding recovery; do not combine (no added benefit).• Steroids don’t work for typical GBS; reserve for select immune–checkpoint–inhibitor cases with expert input.• For treatment-related fluctuations, a repeat course of the initial therapy can be considered in select cases.
Supportive care that saves lives:• Airway & breathing: trend VC/NIF at least twice daily; intubate early if VC < 15 mL/kg, rapidly falling metrics, or bulbar failure.• Autonomic surveillance: watch for tachy/bradyarrhythmias and labile BP; temporary pacing may be needed in severe cases.• DVT prevention: LMWH or heparin + compression; turn, mobilize early.• Pain: prioritize non-opioid neuropathic agents; treat constipation, bladder retention.• Nutrition & skin: enteral feeding if unsafe swallow; meticulous pressure injury prevention.• Rehab starts day 1: PT/OT, respiratory physio, contracture prevention, patient/family education.
Risk & disposition plays:• Up to 20–30% require ventilation—strongest predictor of poor outcome.• Autonomic dysfunction (~20%) can trigger malignant arrhythmias or BP swings—keep on monitors.• Complication shield: aspiration pneumonia, sepsis, PE/DVT, pressure injuries—anticipate and prevent.• Use EGRIS (respiratory insufficiency risk) and mEGOS (functional outcome) to triage level of care, counseling, and resource planning.
Subtypes & nuance:• AIDP predominates in the West; AMAN/AMSAN (axonal) skew more severe and recover slower; Miller Fisher = ophthalmoplegia/ataxia/areflexia. Subtype by NCS may inform prognosis but doesn’t change first-line immunotherapy.
Quality & safety pearls:• Don’t delay IVIg/PE for confirmatory tests if the patient is deteriorating.• Avoid PE when hemodynamically unstable from dysautonomia; prefer IVIg.• IVIg cautions: hyperviscosity/thrombosis risk—hydrate, monitor high-risk patients.• Combination IVIg+PE = no gain; early steroids = harm/no benefit in classic GBS.
Prognosis talk track:• Most regain independent ambulation by 6–12 months, but ~20% have persistent disability; ~3–5% die despite care. Axonal subtype, older age, severe nadir, C. jejuni antecedent, and the need for ventilation worsen outlook.
We close with the hospital bundle that sticks:(1) Admit all suspected; baseline VC/NIF/telemetry + swallow screen.(2) Default to IVIg or PE (one, not both), started early.(3) ICU for bulbar signs, rapid progression, dysautonomia, or EGRIS high-risk.(4) Airway algorithm with objective thresholds (VC <15 mL/kg, falling NIF).(5) Autonomic pathway: continuous monitoring → pacing capable environment.(6) Complication prophylaxis: DVT, pressure, aspiration, sepsis.(7) Rehab-on-admission with daily PT/OT and caregiver education.(8) Score and re-score (EGRIS/mEGOS) to guide expectations and follow-up.
Fast recognition, monitoring that doesn’t blink, and timely IVIg or PE—that’s how you keep GBS safe in the hospital and set the table for recovery.

In this episode of Hospital Medicine Unplugged, we discuss Wernicke–Korsakoff syndrome—spot it early, slam thiamine, stop the slide to irreversible amnesia.
We open with the do-firsts: high clinical suspicion in anyone with alcohol use disorder, malnutrition, bariatric surgery, cancer, hyperemesis, or refeeding. Don’t chase labs; give thiamine now—before glucose—and correct magnesium to make the thiamine work.
Clinical diagnosis that doesn’t miss: the classic triad (confusion, ophthalmoplegia, ataxia) is rare. Use Caine criteria (≥2/4: dietary deficiency, oculomotor signs, cerebellar dysfunction, altered mental state/memory). Do not delay for MRI or thiamine levels; imaging is supportive, not decisive.
Pathophysiology in one breath: thiamine deficiency → mitochondrial failure → lactate build-up → selective injury (mammillary bodies, thalamus, periaqueductal gray). Alcohol compounds the damage by blocking absorption and utilization, so doses must be higher.
Epidemiology & outcomes you’ll actually use: alcohol-related WE is common and progresses to KS more often, while non-alcohol cases are deadlier in-hospital. Most WKS is missed antemortem; once KS lands, profound anterograde/retrograde amnesia with confabulation is often permanent.
Treatment—build the thiamine backbone fast:• Suspected WE: High-dose IV thiamine (e.g., 500 mg IV TID) for 2–3 days, then 250–500 mg IV daily for several days, followed by high-dose oral (e.g., 100–300 mg/day).• Magnesium repletion (target normal) to restore thiamine-dependent enzymes.• Nutrition + electrolytes (mind phosphate for refeeding).• Oral thiamine alone is inadequate in high-risk or symptomatic patients.
If the backbone buckles:• Escalate/extend parenteral dosing if mental status, ocular signs, or gait don’t improve.• Manage agitation/delirium with low-dose agents; avoid sedating away the exam.• Consider MRI only when the diagnosis stays murky after treatment has started.
Prevention plays that save neurons:• Prophylactic parenteral thiamine for all at-risk inpatients (AUD, malnutrition, ICU, post-bariatric, hyperemesis, prolonged NPO/TPN), especially before dextrose.• Order-set defaults: auto-add thiamine to alcohol withdrawal and refeeding pathways; bundle Mg and nutrition consults.• Nix low-value tests (routine serum thiamine) and educate teams that over-treating is safer than missing.
KS reality check: once established, expect severe memory impairment and executive dysfunction; focus on rehab, safety, caregiver training, and secondary prevention (nutrition, AUD treatment) to reduce readmissions.
We close with the system moves: a WKS bundle that (1) screens risk on admission; (2) fires immediate IV thiamine + Mg with nursing-driven protocols; (3) blocks glucose-first orders in high-risk patients; (4) standardizes dosing/taper with auto-stop reminders to avoid under- or over-treating; (5) tracks outcomes (time-to-thiamine, neuro recovery, readmission); (6) hard-wires prevention into alcohol withdrawal, oncology, ICU, and post-bariatric pathways.
Fast, protocolized, and prevention-forward—treat first, test later. Thiamine saves brains; delay steals memories.

In this episode of Hospital Medicine Unplugged, we untangle type 1 vs type 2 NSTEMI—different mechanisms, different playbooks, different outcomes—and why hospital factors often tip the scales for type 2.
We set the stage fast:• Type 1 NSTEMI = atherothrombosis—plaque rupture/erosion → thrombus. Classic chest pain, ischemic ECG, higher use of angiography/PCI, and evidence-based cardioprotective therapy (aspirin + P2Y12, anticoagulation, high-intensity statin, beta-blocker). Protocols are tight and fast.• Type 2 NSTEMI = supply–demand mismatch—no acute coronary thrombosis. Precipitants are hospital triggers: sepsis, anemia, hypoxia, tachyarrhythmia, perioperative stress, hemodynamic instability. Patients are older, multimorbid, with atypical symptoms and non-specific ECGs. Pathway variability and fragmentation are common—especially off cardiology services.
Diagnosis without derailment:• Both need troponin rise/fall + ischemia, but context is king. Type 1 often shows larger, quicker deltas and focal wall-motion loss; type 2 shows modest troponin, diffuse stressors, and may lack a culprit lesion.• When uncertain, lean type 1 to avoid undertreatment—then reclassify as data clarifies.
Management that matches mechanism:• Type 1: run the ACS bundle—DAPT, anticoagulation, high-intensity statin, early invasive strategy for high-risk, plus ACEi/ARB, MRA when indicated.• Type 2: treat the trigger first—oxygenation, rate/rhythm control, volume/pressure optimization, fix anemia/infection. Antithrombotics are not one-size-fits-all; reserve revascularization for proven obstructive CAD or ongoing ischemia. Start/optimize statin, beta-blocker, aspirin when CAD is present or likely. Plan CAD evaluation (often outpatient) once stable.
Why type 2 fares worse:• Higher in-hospital and 1-year mortality, driven by comorbidity and illness severity, not stentable lesions.• Undertreatment and delays: less cardiology involvement, fewer invasive evaluations, and variable secondary prevention despite frequent underlying CAD.
Close the gap—hospital moves that matter:
Create a type 2 NSTEMI pathway: trigger checklists (sepsis/anemia/hypoxia/tachyarrhythmia), hemodynamic targets, and early echo.
Default cardiology consult for diagnostic clarification and CAD strategy.
Order sets that separate type 1 antithrombotic bundles from type 2 trigger-first care, with guardrails on DAPT/anticoagulation.
Secondary prevention audit: statin/beta-blocker/aspirin started when CAD present or suspected; deprescribe when risk > benefit.
Service-agnostic timers for serial ECG/hs-troponin and for escalation if pain/ischemia persists.
Discharge plan for type 2: trigger control, meds reconciliation, outpatient CAD testing, and close follow-up.
Bottom line: Type 1 is a coronary emergency; type 2 is a circulatory stress test you’re failing. Match the treatment to the mechanism, standardize the inpatient pathway for type 2, and you’ll cut noise, delays, and mortality.

In this episode of Hospital Medicine Unplugged, we demystify inpatient thrombophilia workups—why not to test now, who (rarely) to test later, and how to time it so results actually matter.
We start with the do-firsts: treat the clot (full-intensity anticoagulation), document provoking factors, and plan follow-up. Thrombophilia status does not change acute management.
Why routine inpatient testing is discouraged:• Low clinical yield in the hospital; results rarely alter immediate care.• Distorted labs during acute thrombosis/illness or on anticoagulants → false positives/negatives (protein C/S, antithrombin, antiphospholipid tests).• Cost + harm: overdiagnosis, unnecessary anxiety, and inappropriate long-term anticoagulation.• Guidelines agree: ASH 2023 recommends against routine inpatient testing for acute VTE.
Who to actually consider (selectively) and usually as an outpatient:• Young patients with VTE (<40–50).• Unprovoked events or recurrent VTE.• Unusual sites (cerebral/splanchnic/portal).• Strong family history of early VTE.• Pregnancy/postpartum or estrogen-associated VTE—only if results would change future management.
Timing that keeps you out of trouble:• Defer most testing until after the acute phase and off anticoagulation (often around completion of initial therapy, ~3 months).• APS requires persistent positivity ≥12 weeks apart; avoid testing during intercurrent illness or while anticoagulated if it will confound assays.• If you must assess hereditary defects early (rare): favor DNA tests (FVL, prothrombin G20210A) over clot-based assays that DOACs/heparin can skew.
What to test (focused—not a fishing expedition):• Hereditary: factor V Leiden, prothrombin G20210A, antithrombin, protein C, protein S (use functional assays; confirm hereditary deficiency later as needed).• Acquired: antiphospholipid syndrome panel (lupus anticoagulant, anticardiolipin, anti-β2GP1) with correct timing.• Do NOT order MTHFR, factor VIII/IX/XI levels, PAI-1, or broad “hypercoagulable panels”—they don’t guide care.
Interpretation pitfalls to dodge:• Warfarin ↓ protein C/S → false “deficiency.”• Heparin can affect antithrombin and clot-based tests.• DOACs interfere with many clot-based assays (APC resistance, LA).• Acute phase, liver disease, nephrotic syndrome, pregnancy/estrogen can lower natural anticoagulants without heredity.• Always contextualize with provocation status, family history, and timing.
Consult the pros:• Hematology input before ordering improves appropriateness, targeting, and counseling—and prevents waste.
A practical hospital bundle that works:
Default: no inpatient thrombophilia panel for acute VTE.
EHR guardrails: hard-stops or best-practice alerts that route orders to hematology.
Document an outpatient plan (who/when/what to test) at discharge.
If testing later: specify off-anticoagulation timing, which assays, and how results might change therapy (e.g., indefinite anticoagulation in high-risk defects like antithrombin deficiency or triple-positive APS).
Educate patients: results often won’t change today’s treatment; testing aims to inform long-term risk and family planning.
Bottom line: Don’t shotgun thrombophilia tests during admission. Treat the clot, identify provoking factors, and schedule targeted, well-timed outpatient testing—preferably with hematology—so results are reliable, actionable, and worth the poke.

In this episode of Hospital Medicine Unplugged, we put hospital dialysis on the clock—HD for speed and control, PD for stability and flexibility—and show you how to choose fast and safely at the bedside.
We open with what hospitals actually do: HD is the default—3x weekly with AVF/AVG/catheter, machines, trained staff, and water systems—because it rapidly clears solute and removes fluid, perfect for hyperK, acidosis, toxins, and crashing volume overload. PD is used less (infrastructure/training barriers) but can be started urgently at the bedside, shines in hemodynamic instability, and needs no anticoagulation or vascular access.
Mechanics in one breath: HD = diffusion + ultrafiltration across a synthetic membrane (precise, fast, intermittent). PD = the peritoneum with osmotic gradients (slower, continuous, gentler).
Complications you need to anticipate:• HD: intradialytic hypotension, arrhythmias, post-dialysis fatigue; access infections and thrombosis; recovery “hangover.”• PD: peritonitis and exit/tunnel infections; catheter leaks/malposition; longer LOS when infected; potential glucose load/weight gain.
Hospital scenarios—who gets what:• Need rapid correction or toxin removal? → HD.• On pressors/fragile heart/poor access or anticoagulation risk? → PD (gentle, continuous, no heparin).• Already on PD or peri-op? With precautions, PD can often continue—no automatic switch to HD.• Frail/elderly? Assisted PD can match in-center HD for hospitalizations, but survival signals are confounded by frailty—individualize.
Access quick hits: HD (temp or tunneled catheter, AVF/AVG preferred long-term). PD (Tenckhoff catheter, ideally double-cuffed, surgically or IR-placed).
Anticoagulation: HD usually needs UFH/LMWH (or citrate/heparin-free protocols in bleeders). PD needs none unless there’s another indication (e.g., AF/VTE)—bleeding risk drops.
Hemodynamics & metabolism: HD = abrupt shifts (watch BP/ischemia). PD = smoother volume control and often better tolerance; slower for severe hyperK/acidosis.
Infections in a line: HD → catheter-related bacteremia early and often when starting with CVCs. PD → peritonitis drives admissions and technique failure. Prevention bundles (asepsis, lock solutions, exit-site care, fast antibiotics) change outcomes.
Nutrition & volume: Both risk protein-energy wasting. PD loses more protein and absorbs glucose (watch weight and glycemia). HD needs tight sodium/UF targets to curb hypotension; PD uses dialysate tonicity (incl. icodextrin) to tune ultrafiltration.
Comparative outcomes (big picture): mortality differences are modality-neutral after adjustment; PD may have higher early hospitalizations (peritonitis) while HD faces vascular and cardiovascular events. Choose the modality, not the myth—patient factors and hospital resources decide.
Bedside playbook you can use today:
State the goal (rapid correction vs gentle control).
Screen for instability/bleeding/access issues.
Pick HD for emergencies/toxins/precise UF; pick PD for instability, poor access, or anticoagulation concerns.
Bundle prevention: HD (CVC care + anticoagulation plan) / PD (exit-site care + peritonitis protocol).
Monitor smart: HD—telemetry in high-risk, watch UF rate and post-HD labs; PD—daily effluent checks, BP/weight, glucose in diabetics.
Plan the exit: access maturation (AVF), assisted PD for frailty, and clear education on infection red flags.
We close with the system moves: invest in urgent-start PD pathways, staff training, and infection bundles; default to AVF/AVG over CVCs; embed anticoag safety and volume targets; and stop reflex peri-op PD→HD switches. The through-line: match physiology to modality, treat today’s risk, and build tomorrow’s resilience.

In this episode of Hospital Medicine Unplugged, we pit CPAP vs BPAP—who’s first-line, who’s for the exceptions, and how to choose fast at the bedside.
We open with the big picture: CPAP remains first-line for uncomplicated OSA—it’s effective, more cost-effective, and no clear superiority of BPAP for routine outcomes or adherence in general OSA. BPAP shines when ventilation needs a boost or when CPAP isn’t tolerated.
How we call it (efficacy & outcomes):• Both reduce AHI, sleepiness, and improve quality of life.• No clinically meaningful outcome gap between CPAP and BPAP for uncomplicated OSA.• BPAP ≠ better adherence in the general OSA population.
Tolerance & comfort—when BPAP helps:• Pressure intolerance on CPAP? BPAP’s lower EPAP / higher IPAP can ease exhalation, cut aerophagia, and improve comfort.• Switching CPAP→BPAP can reduce mouth dryness, bloating, and improve patient preference in those struggling with fixed pressure.
Special populations—where BPAP earns its keep:• Hypoventilation phenotypes (OHS, COPD overlap): BPAP augments ventilation, drops PaCO₂, and improves gases better than CPAP.• When residual hypercapnia persists on CPAP, escalate to BPAP (consider backup rate if needed).
What the guidelines say (clean takeaways):• Start CPAP for most uncomplicated OSA.• Use BPAP when there’s CPAP intolerance, inadequate AHI/RDI control, or documented hypoventilation/hypercapnia.• In OHS with severe OSA, begin with CPAP; switch to BPAP if hypercapnia persists or CPAP fails.
Quick definitions (what they do):• CPAP = single, constant pressure that splints the upper airway.• BPAP = IPAP/EPAP levels that support ventilation and reduce work of breathing.
Clinical plays you can use tomorrow:• Default: CPAP for routine OSA (optimize mask fit, humidification, behavioral support).• If pressures climb and comfort tanks (exhalation difficulty, aerophagia): trial BPAP.• If daytime hypercapnia/ABG abnormal or OHS/COPD overlap: favor BPAP to clear CO₂.• Refractory residual AHI on CPAP (with good adherence): evaluate for positional/REM-predominant disease, mask leak, then consider BPAP or other modes.
Adherence pearls that actually work:• Fit matters: interface options + proactive leak control.• Humidification to fight dryness.• Early follow-up + troubleshooting beats “set-and-forget.”• Keep SpO₂ targets individualized; in overlap/COPD, avoid over-oxygenation.
Common pitfalls (and fixes):• Chasing comfort with early steroids…oops, wrong episode. Here, the trap is escalating CPAP pressures without addressing exhalation load—switch to BPAP instead.• Assuming BPAP boosts adherence for everyone—it doesn’t; use it selectively.• Ignoring hypercapnia on CPAP—check ABGs/CO₂; upgrade to BPAP if needed.
Fast close:Bottom line: CPAP first for most OSA—effective, economical, evidence-backed. BPAP is your targeted tool for pressure intolerance and hypoventilation syndromes (OHS/COPD overlap), where ventilatory support and CO₂ reduction matter. No broad adherence or outcome edge for BPAP in routine OSA—reserve it for the right patient, at the right time.

In this episode of Hospital Medicine Unplugged, we get hands-on with evidence-based wound care—assess precisely, prevent infection, match the dressing to the wound, and escalate smartly for the tough ones.
We start with the do-firsts: identify wound type (SSI, pressure injury, DFU, traumatic), map size/depth/exudate, scan for infection signs, and hunt barriers (ischemia, diabetes, edema, malnutrition, meds, pressure). Document with photos and a consistent ruler; add ABI/pulses for leg ulcers. Classification guides action (CDC/NHSN class, SSI depth; Wagner/UT/WIfI for DFU).
Cleanse like you mean it: tap water or normal saline for most; high-pressure irrigation for gross contamination. Skip routine antiseptics—use them selectively (e.g., intra-op lavage or NPWT-instillation protocols). Debride early and often: sharp debridement is the fast reset for necrosis/biofilm; enzymatic (collagenase), autolytic (hydrogels/hydrocolloids), pulsed-lavage, and maggots are context plays. Weekly (or tighter) debridement intervals correlate with better healing.
Infection control = stewardship + technique. All wounds are colonized; reserve systemic antibiotics for clinical infection and culture tissue (not swabs) when it matters. Short courses, narrow when able. Topical antimicrobials (silver/iodine) only short-term for critically colonized wounds. Obsess over hand hygiene, contact precautions, and SSI bundles (glucose control, hair clippers, wound protectors, povidone-iodine lavage where appropriate).
Build the moisture-smart dressing plan—no single product wins:• Dry → hydrogels/hydrocolloids (donate moisture, autolysis).• Moderate–heavy exudate → foams, alginates, hydrofibers (absorb, protect peri-wound).• Superficial/low exudate → films/nonadherent covers.• Critically colonized/infected → short-term antimicrobial dressings.Reassess often; change strategy if area isn’t shrinking by ~30–50% in 4 weeks.
When the basics stall, escalate:• NPWT: reduces edema/bioburden, accelerates granulation, lowers SSI in complex/incisional wounds.• NPWT with instillation (polyhexanide, dilute povidone-iodine, acetic acid, silver nitrate) for sloughy, bioburdened wounds.• Biologics/skin substitutes (amniotic/placental matrices, bilayered constructs) for refractory DFU/venous ulcers.• Growth factors/PRP: targeted use in select chronic ulcers.• Oxygen therapies (topical ± hyperbaric) when ischemia coexists and standard care fails.Pick the right patient, right indication, right cost.
Anchor the plan with TIME: Tissue (debride), Inflammation/Infection (control), Moisture (balance), Edge (advance). If the edge isn’t migrating, re-debride, offload/compress, or step up therapy.
Pressure injury prevention is everyone’s job: early Braden, advanced support surfaces, heel offloading, q2h repositioning (tailor to risk), barrier creams, and prophylactic silicone foams at bony points. Bundle it, audit it.
Don’t forget the systemic levers:• Glycemic control, perfusion fixes (revascularize when WIfI says so), edema management.• Nutrition: screen on admit; target 25–30 kcal/kg/day and 1.2–1.5 (up to 2.0) g/kg/day protein; consider high-protein, micronutrient-enriched supplements (vitamin C, zinc, A/D/E) when deficient.• Med review: minimize corticosteroids/immunosuppressants if feasible.
Patient-centered care drives adherence: choose dressings that are comfortable, cost-aware, and easy to change; set clear change intervals; teach signs of infection and offloading/compression techniques.
Disposition & follow-up that stick: photo-track weekly, screen for occult DVT in high-risk leg wounds, and trigger consults early (vascular, ID, plastics, podiatry, rehab). Define success up front (closure vs durable reduction) and time-box each step—no improvement, escalate.
We close with the bedside bundle that moves the needle: (1) classify & measure; (2) cleanse + early debridement; (3) moisture-balanced dressing matched to exudate; (4) antibiotic stewardship; (5) NPWT/escalation for non-progression; (6) pressure-injury bundle hospital-wide; (7) perfusion + glucose + nutrition optimization; (8) weekly team huddles with photos and milestones.
Assess precisely, keep it moist, cut the necrosis, control infection, escalate on time, and never forget the patient factors. That’s how hospitalized wounds heal—reliably and fast.